July 22, 2020 / 10:55 AM / 21 days ago

Glenmark's favipiravir version shows promise in late-stage COVID-19 trial

BENGALURU, July 22 (Reuters) - India’s Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.

About 70% of patients being treated by FabiFlu achieved "clinical cure" by the fourth day of the study, compared with about 45% seen in the group treated with standard supportive care, the company said in a statement reut.rs/3eS12Zt. (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below